M. Docteur GAUTHIER MOREL

Bibliographie

• Actual Persistence of Abatacept in Rheumatoid Arthritis: Results of the French-Ric Network

  2020

  ArticleJournal of Clinical Medicine

• Predictive factors and prognostic value for status epilepticus in newborns

  2019

  ArticleEuropean Journal of Paediatric Neurology

• Management of male osteoporosis: lessons for clinical practice

  2011

  ArticleJoint Bone Spine

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Localisation

Adresses géocodées via la Base Adresse Nationale (api-adresse.data.gouv.fr). Précision indicative.

Lieu de consultation

• CABINET DU DR GAUTHIER MOREL

  5 AVENUE LOUISE, 59110 La Madeleine

  ☎ 0320066320Libéral
  © OpenStreetMap

  📷 Street View ↗🗺️ Maps ↗OSM ↗

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Top publications · les plus citées

• 1

  Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis: Results from the AutoImmunity and Rituximab Registry

  Arthritis care & research · 2012

  📚 78 citations🎯 RCR 3.12Top 15% NIH

  Lire l'abstract Crossref ↓

  AbstractObjectiveRituximab improves articular symptoms in rheumatoid arthritis (RA) and it recently has been shown to be an effective induction therapy for antineutrophil cytoplasmic antibody–associated vasculitis. We assessed the efficacy and safety of rituximab in a real‐life clinical setting among patients with systemic rheumatoid vasculitis (SRV).MethodsWe analyzed data from the AutoImmunity and Rituximab registry, which includes patients with autoimmune diseases treated with rituximab.ResultsOf the 1,994 patients with RA enrolled in the registry, 17 were treated with rituximab for active SRV. At baseline, the mean Birmingham Vasculitis Activity Score for RA (BVAS/RA) was 9.6, with a mean prednisone dosage of 19.2 mg/day. After 6 months of rituximab therapy, 12 patients (71%) achieved complete remission of their vasculitis, 4 had a partial response, and 1 died with uncontrolled vasculitis. Mean BVAS/RA was reduced to 0.6 and mean prednisone dosage to 9.7 mg/day. At 12 months, 14 patients (82%) were in sustained complete remission. Severe infection occurred in 3 patients, corresponding to a 6.4 per 100 patient‐years rate. In the 6 patients who received further rituximab as maintenance therapy between months 6 and 12, no relapse of vasculitis was observed. However, among the 9 patients who did not, a relapse was observed in 3 patients who were treated with methotrexate alone. Remission was reestablished by reintroducing rituximab in 2 cases.ConclusionComplete remission of SRV was achieved in nearly three‐fourths of patients receiving rituximab in daily practice, with a significant decrease in daily prednisone dosage and an acceptable toxicity profile. Rituximab represents a suitable therapeutic option to induce remission in SRV, but maintenance therapy seems to be necessary.

• 2

  Treatment of late-presenting developmental dislocation of the hip by progressive orthopaedic reduction and innominate osteotomy. Our results with more than 30 years of follow up

  Journal of children's orthopaedics · 2011

  📚 24 citations🎯 RCR 1.67🔓 Open Access

  Lire l'abstract Crossref ↓

  Background The treatment of late-presenting developmental dislocation of the hip (DDH) is still controversial. A consecutive series of 32 patients not previously treated (43 hips, Tönnis grade 3 or 4) underwent progressive closed reduction followed immediately by innominate osteotomy between 1964 and 1976. They were between 1.5 and 5 years old at the time of pelvic osteotomy. This study was designed to check the outcome of these patients more than 30 years later. Methods Eight patients living outside of France (North Africa) could not be reached and one patient had died of an unrelated cause. The remaining 23 patients (32 hips) were reviewed with clinical assessment (Merle d'Aubigné, Harris and Western Ontario and McMaster Universities Osteoarthritis Index [WOMAC] scores) and anteroposterior (AP) pelvic radiograph. This represents a 75% rate of follow up at 31 to 44 years post-operatively. Results In two patients, surgery was repeated due to residual subluxation. Only one patient needed a total hip replacement (THR) 33 years after initial treatment. The Merle d'Aubigné, Harris and WOMAC scores for the surviving hips were excellent or good in almost 80% of the cases. In four cases, radiographic signs “at risk for” osteoarthritis were present. Regularity of the femoral head was perfect in seven hips, regular in 18 and irregular in six. According to the Severin–Seringe classification, 25 hips could be classified as group I (14 group IA and 11 group IB), three group II and three group VII. Conclusion The long-term results of non-previously treated late-presenting DDH by the technique of progressive closed reduction followed by innominate osteotomy are quite good and compare favourably with the long-term results of open reduction with the same osteotomy.

• 3

  Osteoporosis and Alzheimer´s disease (or Alzheimer´s disease and Osteoporosis)

  Ageing research reviews · 2024

  📚 14 citations🎯 RCR 2.78Top 18% NIH

Publications scientifiques (18) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Partager cette fiche